Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
ANZEMET (dolasetron mesylate) - Withdrawal of 20 mg/mL Intravenous Injection Due to Potential Risk of Arrhythmias - For the Public
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
(PDF Version - 52 K)Contact: Marketed Health Products Directorate
The Health Products and Food Branch (HPFB) posts on the Health Canada Web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.
This is duplicated text of a letter from Sanofi-aventis Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
PUBLIC COMMUNICATION
Health Canada Endorsed Important Safety Information on ANZEMET intravenous injection
April 28, 2011
Subject: Withdrawal of ANZEMET® (dolasetron mesylate) injection due to potential risk of abnormal heart rhythm
Sanofi-aventis Canada Inc., in collaboration with Health Canada would like to inform patients of the withdrawal of ANZEMET® (dolasetron mesylate) intravenous injection as it is no longer to be used to prevent nausea and vomiting associated with chemotherapy.
ANZEMET® helps prevent nausea and vomiting associated with chemotherapy. It is to be used only in adults.
New data show that the injectable form of ANZEMET® can potentially increase the risk of abnormal heart rhythm which may result in serious cardiac problems at the doses recommended for the prevention of nausea and vomiting. The injection form of ANZEMET® will be removed from the Canadian market as of May 10, 2011.
Sanofi-aventis is working with Health Canada to revise the Product Monograph for ANZEMET® tablets to update this new safety information.
- ANZEMET® injection will no longer be used to prevent nausea and vomiting associated with chemotherapy.
- ANZEMET® tablets for oral use may still be used as per the conditions described in the ANZEMET® Product Monograph.
- Patients treated with ANZEMET® should immediately report to their doctor if they experience any symptoms suggesting abnormal heart rhythm such as: dizziness, palpitations, fainting or seizures.
Please speak with your doctor or pharmacist if you have any related concerns or if you experience any other unexpected effects while taking ANZEMET®.
Managing marketed health product-related side effects depends on health professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported side effects of marketed products are generally presumed to underestimate the risks associated with health product treatments. Any case of serious heart rhythm problems or other serious or unexpected side effects in patients receiving ANZEMET® (dolasetron mesylate) should be reported to sanofi-aventis Canada Inc. or Health Canada at the following addresses:
Sanofi-aventis Canada Inc.
2150 St-Elzear Blvd. West
LAVAL, Quebec
H7L 4A8
Telephone: 1-800-267-7927
The Product Monograph and a copy of this Important Safety Information can be accessed online at www.sanofi-aventis.ca
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Reporting Form and:
- Fax toll-free to 1-866-678-6789, or
- Mail to: Canada Vigilance Program
Health Canada
Postal Locator 0701E
Ottawa, Ontario K1A 0K9
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions regarding the new important safety update, please contact sanofi-aventis Canada Inc. toll free at 1-800-265-7927.
Sincerely,
original signed by
Franca Mancino, M.Sc.
Senior Director, Regulatory Affairs, Pharmacovigilance
and Quality and Compliance
sanofi-aventis Canada Inc.
